Carlton South Vic 3053, Australia
Go to Investors Hub
info@radiopharmtheranostics.com

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Leave a Reply

Your email address will not be published.Required fields are marked *

More Announcements & Updates

Initial Director’s Interest Notice – LA
Application for quotation of securities – RAD
Notification regarding unquoted securities – RAD
Change in substantial holding PH
Categories
Announcements
Announcements
Annual Reports
Annual Reports
Presentations
Presentations
News
News
Recent News
Analyst ReportsAnnouncementsAnnual ReportsInvestor PresentationsRAD ArticlesUpdates
Tags
Tags
Appendix 2A (1) Appendix 3B (1) Change of Director's Interest Notice (1) Cleansing Notice (1) PDF (34) Periodic Reports (25) Price Sensitive (84) Progress Report (2) Video (3) With Summary (2) With Video (4)
Archives
Archives
RSS RSS
Close
Search

Hit enter to search or ESC to close

cookie By using this website, you agree to our cookie policy. Close